Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability
- 18 February 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Molecular Medicine
- Vol. 89 (6), 595-602
- https://doi.org/10.1007/s00109-011-0737-3
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant LesionsCancer Prevention Research, 2009
- Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancerBritish Journal of Cancer, 2009
- A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid TumorsClinical Cancer Research, 2009
- Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapyAnnals of Oncology, 2009
- Bortezomib and EGCG: no green tea for you?Blood, 2009
- Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in MiceJournal of Clinical Oncology, 2009
- Synergistic inhibition of head and neck tumor growth by green tea (−)‐epigallocatechin‐3‐gallate and EGFR tyrosine kinase inhibitorInternational Journal of Cancer, 2008
- Epigallocatechin-3-Gallate Enhances CD8+ T Cell–Mediated Antitumor Immunity Induced by DNA VaccinationCancer Research, 2007
- Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell CarcinomaThe Oncologist, 2007
- Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implicationsBlood, 2006